title: Vasculitis associated with all trans retinoic acid (ATRA) in a case with acute promyelocytic leukemia.
abstract: All trans retinoic acid is the drug of choice in the treatment of acute promyelocytic leukemia. But this drug has some side effects, some of which may be life-threatening. Retinoic acid syndrome is the most frequent and dangerous side effect of this differentiation inducing agent. Other side effects include Sweet's syndrome, vasculitis, hypercalcemia, bone marrow necrosis and fibrosis, thromboembolic events, erythema nodosum, granulomatous proliferation and some pulmonary complications. Here, we report vasculitis in a case with APL treated with ATRA and review the literature.
authors.affiliation: Department of Oncology, Cukurova University, Faculty of Medicine, Cukurova University Adana, Turkey. sepay@cu.edu.tr
authors.forename: Semra
authors.initials: S
authors.lastname: Paydas
authors.forename: Sinan
authors.initials: S
authors.lastname: Yavuz
authors.forename: Umut
authors.initials: U
authors.lastname: Disel
authors.forename: Berksoy
authors.initials: B
authors.lastname: Sahin
authors.forename: Tugba
authors.initials: T
authors.lastname: Canbolat
authors.forename: Ilhan
authors.initials: I
authors.lastname: Tuncer
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005334:Fever / Q000139:chemically induced; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D012074:Remission Induction; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects*; D014657:Vasculitis / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D014212:Tretinoin; D008775:Methylprednisolone